Compugen Ltd
NASDAQ:CGEN

  • LAST PRICE
    1.4100
  • TODAY'S CHANGE (%)
    -0.0400 (-2.7586%)
  • Bid / Lots
    1.4000/ 15
  • Ask / Lots
    1.4100/ 3
  • Open / Previous Close
    1.4600 / 1.4500
  • Day Range
    1.3750
    1.5000
  • 52 Week Range
    0.6200
    3.0301
  • Volume
    277,625

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Nov 12, 2024

      Show headlines and story abstract

    • 7:11AM ET on Tuesday Nov 12, 2024 by MT Newswires
      Companies Mentioned: CGEN
      07:11 AM EST, 11/12/2024 (MT Newswires) -- ...

    • 7:10AM ET on Tuesday Nov 12, 2024 by MT Newswires
      Companies Mentioned: CGEN
      07:10 AM EST, 11/12/2024 (MT Newswires) -- ...

    • 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: CGEN

    • 7:00AM ET on Tuesday Nov 12, 2024 by Dow Jones
      Companies Mentioned: CGEN

      achievements expressed or implied by such forward-looking statements. Among these risks: Compugen's business model is substantially dependent on entering into collaboration agreements with third parties and Compugen may not be successful in generating adequate revenues or commercializing aspects of its business model; Compugen may not be able to advance its internal clinical stage programs through clinical development or manufacturing or successfully partner or commercialize them, or obtain marketing approval, either alone or with a collaborator, or may experience significant delays in doing so; clinical development involves a lengthy and expensive process, with an uncertain outcome and Compugen may encounter substantial delays or even an inability to begin clinical trials for any specific product or may not be able to conduct or complete its trials on the timelines it expects; Compugen has limited experience in the development of therapeutic product candidates, and it may be unable to implement its business strategy; the general market, political and economic conditions in the countries in which Compugen operates, including Israel; and the effect of the evolving nature of the recent war in in Israel. These risks and other risks are more fully discussed in the "Risk Factors" section of Compugen's most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission (SEC) as well as other documents that may be subsequently filed by Compugen from time to time with the SEC. In addition, any forward-looking statements represent Compugen's views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

  • Nov 11, 2024

Peers Headlines